Heron Therapeutics trades as part of the drug manufacturers industry and is part of the healthcare sector. The company CEO is Barry D. Quart. Heron Therapeutics Inc is a biotechnology company, developing products to address unmet medical needs. It is developing novel, patient-focused solutions that apply its science and technologies to already-approved pharmacological agents.
Previous Intraday Performance:
The HRTX shares had a previous change of 1.02% which opened at 17.84 and closed at 17.87. It moved to an intraday high of 17.95 and a low of 17.55.
Over the last five trading days, HRTX shares returned 0.79% and in the past 30 trading days it returned -25.85%. Over three months, it changed -36.47%. In one year it has changed -49.02% and within that year its 52 week high was 42.90 and its 52 week low was 16.20. HRTX stock is 10.31% above its 52 week low.
Our calculations result in a 200 day moving average of 27.09 and a 50 day moving average of 21.10. Right now, HRTX stock is trading -34.02% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.
Business Wire: IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Heron Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The company has a market cap of $1.4b with 79.2m shares outstanding and a float of 77.6m shares. Trading volume was 675,833 shares and has experienced an average volume of 1,591,505 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is good.
The last annual reported EPS for Heron Therapeutics was -2.47 which ended on 31st of December 2018. Based on 5 analyst estimates, the consensus EPS for the next quarter is -0.46.
Below was the last reported quarterly diluted earnings per share:
|1st||Qtr 2019||Reported 05-09-2019:||-0.80|
|4th||Qtr 2018||Reported 02-22-2019:||-0.63|
|3rd||Qtr 2018||Reported 11-07-2018:||-0.49|
|2nd||Qtr 2018||Reported 08-08-2018:||-0.54|
|1st||Qtr 2018||Reported 05-10-2018:||-0.81|
Base on our calculations, the intrinsic value per share is 131.91, which means it might be undervalued and has a margin of safety of 86.45%.
EPS growth is an important number as it indicates the future prospects of Heron Therapeutics; the EPS growth rate, as it is typically called, is usually expressed as a percentage, which at this time is hard to estimate, but revenue growth has been 89.20% over the last twelve months.
Indicators Also to Watch:
The beta was calculated to be 1.60.
Based on last reported financials, the company’s return on assets is -61.24%, price-to-sales is 14.37 and price-to-book is 4.22.
Company Score Card:
Results are out of six:
5 : Growth Expectations Result
5 : Financial Safety Result
0 : Past Performance Result
2 : Valuation Result
0 : Dividend Safety Result
3 : Overall Result